Wide-Swensson D H, Ingemarsson I, Lunell N O, Forman A, Skajaa K, Lindberg B, Lindeberg S, Marsàl K, Andersson K E
Department of Obstetrics and Gynecology, University Hospital, Lund, Sweden.
Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):872-8. doi: 10.1016/0002-9378(95)90357-7.
Our purpose was to study the effects of isradipine, a dihydropyridine calcium channel blocker, on mother and fetus in the treatment of hypertensive disorders of pregnancy.
The investigation was performed as a two-group, parallel, double-blind multicenter study of isradipine versus placebo. Fifty-four women were randomized to treatment with isradipine slow-release capsules given orally 5 mg twice a day and 57 to a placebo group.
Isradipine lowered the maternal mean arterial blood pressure effectively in women with nonproteinuric hypertension but did not do so in women with proteinuria at recruitment or appearing during treatment. Blood flow in the umbilical artery and maternal renal and liver function were not influenced by treatment. Isradipine had few side effects and was well tolerated.
Calcium channel blockade with isradipine is effective for treatment of nonproteinuric hypertension but not in preeclampsia.
我们的目的是研究二氢吡啶类钙通道阻滞剂伊拉地平对妊娠高血压疾病患者母婴的影响。
该研究为伊拉地平与安慰剂的两组平行双盲多中心研究。54名女性被随机分配至口服伊拉地平缓释胶囊组，每日2次，每次5mg；57名女性被分配至安慰剂组。
伊拉地平可有效降低非蛋白尿性高血压女性的母体平均动脉血压，但对入组时或治疗期间出现蛋白尿的女性无效。治疗未影响脐动脉血流以及母体的肾和肝功能。伊拉地平副作用少，耐受性良好。
伊拉地平进行钙通道阻滞对非蛋白尿性高血压有效，但对先兆子痫无效。
